Results 81 to 90 of about 578 (168)

Risk factors for severe sting reactions and side effects during venom immunotherapy [PDF]

Understanding the risk factors leading to severe systemic sting reactions (SSRs) is crucial for initiating venom immunotherapy (VIT) and for educating affected individuals and their families.
Košnik, Mitja, Marta, Giorgia, Sturm, Gunter, Schadelbauer, Eva, Bonadonna, Patrizia   +4 more
core   +1 more source

QUANTITATIVE ASSESSMENT of the compliance with a once-daily sublingual immunotherapy regimen in real life

, 2006
Allergen-specific immunotherapy given as subcutaneous injections (SCIT) remained for decades the only available administration route. SCIT is effective and safe when properly prescribed and administered, but a remote risk of severe side effects ...
LOMBARDI C, RIDOLO, Erminia, PECORA S, PASSALACQUA G, SACERDOTI G, CADARIO G, SCHIAVINO D, SENNA G., AMOROSO S, ANTONICELLI L, DI GIOACCHINO M, MUSARRA A   +11 more
core   +1 more source

Rewiring of gene networks underlying mite allergen-induced CD4+Th-cell responses during immunotherapy

, 2020
Background Multiple regulatory mechanisms have been identified employing conventional hypothesis-driven approaches as contributing to allergen-specific immunotherapy outcomes, but understanding of how these integrate to maintain immunological homeostasis
Holt, Patrick G., Anderson, Denise, Troy, Niamh M., Serralha, Michael, Jones, Anya C., Bosco, Anthony, Hartmann, Rochelle, Mallon, Dominic, Holt, Barbara   +8 more
core   +1 more source

Omalizumab Updosing in Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global population.
Metz, Martin||, Vadasz, Zahava||, Kocatürk, Emek||, Giménez-Arnau, Ana M.||   +3 more
openaire   +1 more source

Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report

, 2011
P>Chronic spontaneous urticaria, formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is more common than previously thought. At any time, 0.5-1% of the population suffers from the disease (point prevalence).
Hide, Zuberbier, T., Grattan, C. E. H., M., Saini, S. S., Kalogeromitros, D., K., J., Bousquet, J., Godse, K. V., Bindslev-Jensen, C., Canonica, G. W., Gimenez-Arnau, A., Church, M., Bousquet, P. J., Maurer, M., Weller, K., Kaplan, A. P., Greaves, M. W., Zhu, X.   +19 more
core   +1 more source

Lower body mass index was an independent factor of omalizumab dose escalation in adult patients with chronic spontaneous urticaria

Omalizumab is commonly used at a standard dose of 300 mg every 4 weeks for chronic spontaneous urticaria (CSU), but a subset of patients requires dose escalation.
Terzi, Leyla Huseynova, ZEYREK, METİN, Evans, Sibel Ersoy, Memisoglu, Ihsan Berkay, AKDOĞAN, NESLİHAN, Armagan, Basak Yalici, GÜLSEREN, DUYGU, Balan, Kerem, Gunaydin, SİBEL   +8 more
core   +1 more source

Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines [PDF]

Journal of the American Academy of Dermatology, 2020
Sofianne, Gabrielli, Michelle, Le, Elena, Netchiporouk, Barbara, Miedzybrodzki, Sharon, Baum, Shoshana, Greenberger, Petra, Staubach-Renz, Moshe, Ben-Shoshan   +7 more
openaire   +2 more sources

Comment on “Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines” [PDF]

Journal of the American Academy of Dermatology, 2020
Yashdeep Singh, Pathania, Anil, Budania
openaire   +2 more sources

The future of sublingual immunotherapy.

, 2009
Sublingual immunotherapy (SLIT) is currently the most prescribed form of allergen immunotherapy in many European countries. Its use has been accepted in the international consensus publications, and recently also the scepticism of USA scientists is ...
DUSE, MARZIA, M. Duse, M. L. Rosa, F. Marcucci, MARSEGLIA, GIAN LUIGI, M. La Rosa, C. Incorvaia, F. Frati, G. L. Marseglia   +8 more
core  

Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp.

, 2023
BACKGROUND: Peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) is the first oral immunotherapy indicated for children aged 4 to 17 years with peanut allergy. There are limited real-world data on patients treated with PTAH.
McCann, William, Shroba, Jodi, Tilles, Stephen, Portnoy, Jay M, Donelson, Sarah M, Latremouille-Viau, Dominick, Bungay, Rebecca, Romdhani, Hela, Chen, Kathleen   +8 more
core